Immobilized Human IGFBP-4, His tag at 2 μg/mL (50 μL/well) can bind Human IGF-2 Protein, hFc Tag (Cat. No. S0A4045) with EC50 of 39.02-43.08 ng/ml.
Product Details
Product Details
Product Specification
Species | Human |
Accession | P22692 |
Amino Acid Sequence | DEAIHCPPCSEEKLARCRPPVGCEELVREPGCGCCATCALGLGMPCGVYTPRCGSGLRCYPPRGVEKPLHTLMHGQGVCMELAEIEAIQESLQPSDKDEGDHPNNSFSPCSAHDRRCLQKHFAKIRDRSTSGGKMKVNGAPREDARPVPQGSCQSELHRALERLAASQSRTHEDLYIIPIPNCDRNGNFHPKQCHPALDGQRGKCWCVDRKTGVKLPGGLEPKGELDCHQLADSFREGGGGSHHHHHHHHHH. |
Expression System | HEK293 |
Molecular Weight | 27.6 kDa (Reducing) |
Purity | >95% by SDS-PAGE |
Endotoxin | <1EU/μg |
Conjugation | Unconjugated |
Tag | His Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | 0.2M PBS, pH7.4 |
Reconstitution | Reconstitute at less than 1 mg/mL according to the size in deionized water after rapid centrifugation. |
Stability & Storage | Within 1 month, 2 to 8 °C under sterile conditions after reconstitution. 12 months from date of receipt, -20 to -80 °C as supplied. Avoid repeated freeze-thaw cycles. |
Background
IGFBP-4 (insulin-like growth factor binding protein 4) binds to insulin-like growth factor 1 (IGF-1) and IGF-2 with high affinity and inhibits IGF effects in vitro. All members of the IGFBP family bind to IGF-I and IGF-II with approximately equal affinity, but IGFBP-4 binds to IGF2 better than IGF1. It contains a N-terminal domain of IGFBP and a thyroglobulin 1 type domain. IGFBP prolongs the half-life of insulin-like growth factor and has been shown to inhibit or stimulate the stimulative effects of insulin-like growth factor on cell culture. They alter the interaction of IGF with its cell surface receptors. IGFBP-4 is a unique protein that consistently inhibits multiple cancer cells in vivo and in vitro.This product is the recombinant human IGFBP-4 protein expressed from human 293 cells (HEK293).
Picture
Picture
Bioactivity

SDS-PAGE


